XML 31 R21.htm IDEA: XBRL DOCUMENT v3.25.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues
Revenues from collaboration and license agreements as a percentage of total revenues for the three and six months ended June 30, 2025 were as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
20252025
Eli Lilly
98 %73 %
Pfizer Inc.— %20 %
Other license agreements2 %7 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
June 30,
2025		December 31,
2024		June 30,
2024		December 31,
2023
Cash and cash equivalents$38,344 $41,918 $27,786 $45,204 
Non-current restricted cash1,500 1,500 — 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$39,844 $43,418 $27,786 $46,704 
Schedule of Restricted Cash
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
June 30,
2025		December 31,
2024		June 30,
2024		December 31,
2023
Cash and cash equivalents$38,344 $41,918 $27,786 $45,204 
Non-current restricted cash1,500 1,500 — 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$39,844 $43,418 $27,786 $46,704